Early or late antibiotic intervention prevents helicobacter pylori-induced gastric cancer in a mouse model

Cancer Letters

Volumn 359, Issue 2, 2015, Pages 345-351

  Zhang, Songhua ^a   Lee, Dong Soo ^b   Morrissey, Rhiannon ^c   Aponte Pieras, Jose R ^a   Rogers, Arlin B ^d   Moss, Steven F ^a  

^a BROWN UNIVERSITY   (United States)

^b The Catholic University of Korea   (South Korea)

^c SALVE REGINA UNIVERSITY   (United States)

^d TUFTS UNIVERSITY   (United States)

Author keywords

Chemokines; Gastric cancer; Helicobacter pylori; Inflammation; Mouse model

Indexed keywords

CLARITHROMYCIN; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; METRONIDAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEPRAZOLE; PROTEIN P27; RANTES; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; CXCL10 PROTEIN, MOUSE; CXCL9 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM DETECTION; CONTROLLED STUDY; DRUG EFFICACY; EARLY INTERVENTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; EXPERIMENTAL MODEL; GASTRITIS; GASTROINTESTINAL DYSPLASIA; HELICOBACTER INFECTION; HISTOPATHOLOGY; HYPERPLASIA; INTESTINE METAPLASIA; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; STOMACH ATROPHY; STOMACH CANCER; THERAPY DELAY; TREATMENT DURATION; WILD TYPE MOUSE; ANIMAL; BLOOD; C57BL MOUSE; COMPLICATION; GENE EXPRESSION; GENETICS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGY; MICROBIOLOGY; PATHOLOGY; PRECANCEROUS CONDITIONS; STOMACH MUCOSA; STOMACH TUMOR;

HELICOBACTER PYLORI; MUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CLARITHROMYCIN; GASTRIC MUCOSA; GENE EXPRESSION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MICE, INBRED C57BL; OMEPRAZOLE; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS;

EID: 84922992956     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.028     Document Type: Erratum

References (44)

1. McColl K.E. Clinical practice. Helicobacter pylori infection. N. Engl. J. Med 2010, 362(17):1597-1604. pmid:20427808.
2. Moss S.F., et al. Mechanisms of disease: inflammation and the origins of cancer. Nat. Clin. Pract. Oncol 2005, 2:90-97. pmid:16264881.
3. Wroblewski L.E., et al. Helicobacter pylori in gastric carcinogenesis: mechanisms. Gastroenterol. Clin. North Am 2013, 42:285-298. pmid:23639641.
4. Chey W.D., et al. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol 2007, 102:1808-1825. pmid:17608775.
5. Morgan D.R., et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA 2013, 309:578-586. pmid:23403682.
6. Camargo M.C., et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am. J. Gastroenterol 2014, 109:485-495. pmid:24589670.
7. Fuccio L., et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann. Intern. Med 2009, 151:121-128. pmid:19620164.
8. Jemal A., et al. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90. pmid:21296855.
9. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006, 118:3030-3044. pmid:16404738.
10. Correa P., et al. A model for gastric cancer epidemiology. Lancet 1975, 306:58-60. pmid:49653.
11. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992, 52:6735-6740. pmid:1458460.
12. Mera R., et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005, 54:1536-1540. pmid:15985559.
13. IARC working group on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. Lyon, 7-14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum 1994, 61:1-241. pmid:7715068.
14. Kim D.H., et al. Long-term evaluation of mice model infected with Helicobacter pylori: focus on gastric pathology including gastric cancer. Aliment. Pharmacol. Ther 2003, 18(Suppl. 1):14-23. pmid:12925137.
15. Fox J.G., et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res 2003, 63:942-950. pmid:12615707.
16. Franco A.T., et al. Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc. Natl Acad. Sci. U.S.A. 2005, 102:10646-10651. pmid:16027366.
17. Sugimoto M., et al. Gastric mucosal interleukin-17 and -18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Sci 2009, 100:2152-2159. pmid:19694753.
18. Lee A., et al. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997, 112:1386-1397. pmid:9098027.
19. Kuzushita N., et al. p27kip1 deficiency confers susceptibility to gastric carcinogenesis in Helicobacter pylori-infected mice. Gastroenterology 2005, 129:1544-1556. pmid:16285954.
20. Rogers A.B., et al. Helicobacter-based mouse models of digestive system carcinogenesis. Methods Mol. Biol 2009, 511:267-295. pmid:19347301.
21. Lee C.W., et al. Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res 2008, 68:3540-3548. pmid:18441088.
22. van Zanten S.J., et al. Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. Antimicrob. Agents Chemother 2003, 47:2249-2255. pmid:12821476.
23. Lee C.W., et al. Wild-type and interleukin-10-deficient regulatory T cells reduce effector T-cell-mediated gastroduodenitis in Rag2-/- mice, but only wild-type regulatory T cells suppress Helicobacter pylori gastritis. Infect. Immun 2007, 75:2699-2707. pmid:17353283.
24. Mikula M., et al. Quantitative detection for low levels of Helicobacter pylori infection in experimentally infected mice by real-time PCR. J. Microbiol. Methods 2003, 55:351-359. pmid:14529956.
25. Komatsu K., et al. Pathogenesis of herpetic stromal keratitis in CCR5- and/or CXCR3-deficient mice. Curr. Eye Res 2008, 33:736-749. pmid:18798077.
26. Garhart C.A., et al. Clearance of Helicobacter pylori Infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect. Immun 2002, 70:3529-3538. pmid:12065492.
27. Cai X., et al. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. Gastroenterology 2005, 128:1937-1952. pmid:15940628.
28. Wilson K.T., et al. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007, 133:288-308. pmid:17631150.
29. Yamaoka Y., et al. Chemokines in the gastric mucosa in Helicobacter pylori infection. Gut 1998, 42:609-617. pmid:9659152.
30. Eck M., et al. CXC chemokines Gro (alpha)/IL-8 and IP-10/MIG in Helicobacter pylori gastritis. Clin. Exp. Immunol 2000, 122:192-199. pmid:11091274.
31. Romero-Gallo J., et al. Effect of Helicobacter pylori eradication on gastric carcinogenesis. Lab. Invest 2008, 88:328-336. pmid:18180700.
32. Resnick M.B., et al. Global analysis of the human gastric epithelial transcriptome altered by Helicobacter pylori eradication in vivo. Gut 2006, 55:1717-1724. pmid:16641130.
33. Goll R., et al. Alterations in antral cytokine gene expression in peptic ulcer patients during ulcer healing and after Helicobacter pylori eradication. Scand. J. Immunol 2008, 67:57-62. pmid:18028289.
34. Zhang S., et al. Cytokine-stimulated T lymphocyte proliferation is regulated by p27Kip1. J. Immunol 2000, 165:6270-6277. pmid:11086062.
35. Singh A., et al. Regulation of memory CD8 T-cell differentiation by cyclin-dependent kinase inhibitor p27Kip1. Mol. Cell. Biol 2010, 30:5145-5159. pmid:20805358.
36. Jatzek A., et al. p27 (Kip1) negatively regulates the magnitude and persistence of CD4 T cell memory. J. Immunol 2012, 189:5119-5128. pmid:23071285.
37. Jatzek A., et al. T-cell intrinsic and extrinsic mechanisms of p27Kip1 in the regulation of CD8 T-cell memory. Immunol. Cell Biol 2013, 91:120-129. pmid:23207280.
38. Yamaoka Y., et al. Natural history of gastric mucosal cytokine expression in Helicobacter pylori gastritis in Mongolian gerbils. Infect. Immun 2005, 73:2205-2212. pmid:15784564.
39. Colvin R.A., et al. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J. Biol. Chem 2004, 279:30219-30227. pmid:15150261.
40. Groom J.R., et al. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol 2011, 89:207-215. pmid:21221121.
41. Hahm K.B., et al. Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment. Pharmacol. Ther 2003, 18(Suppl. 1):24-38. pmid:12925138.
42. Kraft M., et al. IFN-gamma synergizes with TNF-alpha but not with viable H. pylori in up-regulating CXC chemokine secretion in gastric epithelial cells. Clin. Exp. Immunol 2001, 126:474-481. pmid:11737065.
43. Rajkumar T., et al. Identification and validation of genes involved in gastric tumorigenesis. Cancer Cell Int 2010, 10:45. pmid:21092330.
44. Lee H.J., et al. CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting. World J. Gastroenterol 2014, 20:1681-1693. pmid:24587647.